• LLY
• NVO

US Medicaid programs say cost a key factor for weight-loss drug coverage, survey finds

Most U.S. states do not cover Novo Nordisk and Eli Lilly's weight-loss drugs in Medicaid, primarily due to cost, while spending on Medicaid is expected to rise amid declining membership.

• LLY

Lilly sues online vendors, medical spa over copycat weight-loss drugs

Eli Lilly has filed lawsuits against vendors for selling products claiming to contain tirzepatide, aiming to protect consumers from misleading claims and potential safety risks.

• CTLT
• LLY
• NVO

US Senator Warren calls for scrutiny of Novo Holdings' Catalent deal

Senator Elizabeth Warren urges antitrust review of Novo Nordisk's $16.5 billion acquisition of Catalent, citing concerns over potential anti-competitive advantages in the obesity drug market.

• AZN
• LLY
• MBX
• NVO

MBX Biosciences earns Buy rating at three investment firms

Three investment firms have given MBX Biosciences a Buy rating, citing promising treatments and potential catalysts that could significantly boost the company's stock value.

• LLY

Compounding group sues FDA for removing Lilly's weight loss drug from shortage list

A drug compounding industry group sued the FDA over removing Eli Lilly's diabetes and weight loss drugs from the shortage list, claiming it harms access during ongoing shortages.

• CI
• CVS
• LLY
• NVO
• SNY
• UNH

Texas attorney general sues insulin makers and pharmacy middlemen over high costs

Texas AG Ken Paxton has sued insulin manufacturers and PBMs for inflating insulin prices, alleging collusion to benefit from high costs, challenging prior FTC actions targeting only PBMs.

• BIIB
• LLY

UBS sees more downside and than upside in Biogen stock

UBS analysts lowered Biogen's stock price target and EPS estimates, citing challenges with growth assets and competition, leading to a respective 30% and 14% decline projections.

• HIMS
• LLY
• NVO

Hims & Hers shares dip 9% after FDA says Lilly's weight-loss drug not in shortage

• LLY
• NOVOb
• NVO

Novo Nordisk stock valuation ‘very compelling’ says Bank of America

Bank of America lowers Novo Nordisk's price target amid cautious expectations for Wegovy and Ozempic, while maintaining a Buy rating due to upcoming CagriSema trial data potential.

• LLY

Lilly to invest $4.5 billion for new Indiana facility

Eli Lilly plans to invest $4.5 billion in a new Indiana facility for advanced drug manufacturing, increasing its U.S. investment to over $23 billion since 2020.